Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Inovio Pharmaceuticals, Inc. (INO) - free report >>
Immunocore Holdings PLC Sponsored ADR (IMCR) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inovio Pharmaceuticals, Inc. (INO) - free report >>
Immunocore Holdings PLC Sponsored ADR (IMCR) - free report >>
Image: Bigstock
Strength Seen in Immunocore Holdings PLC Sponsored ADR (IMCR): Can Its 10.2% Jump Turn into More Strength?
Immunocore Holdings PLC Sponsored ADR (IMCR - Free Report) shares ended the last trading session 10.2% higher at $58.12. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19.9% gain over the past four weeks.
Last month, the company presented promising data from a phase I study evaluating IMC-F106C at the ESMO 2022 congress. Data from phase I dose escalation study showed that treatment with IMC-F106C was well tolerated and resulted in durable responses across multiple solid tumor types. This might have been driving the share price rally.
This company is expected to post quarterly loss of $0.27 per share in its upcoming report, which represents a year-over-year change of +71.6%. Revenues are expected to be $37.86 million, up 363.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Immunocore Holdings PLC Sponsored ADR, the consensus EPS estimate for the quarter has been revised 31.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on IMCR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Immunocore Holdings PLC Sponsored ADR belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Inovio Pharmaceuticals (INO - Free Report) , closed the last trading session 9.3% higher at $1.88. Over the past month, INO has returned 3.6%.
Inovio's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.29. Compared to the company's year-ago EPS, this represents no change. Inovio currently boasts a Zacks Rank of #3 (Hold).